Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AMYT

Amryt Pharma (AMYT) Stock Price, News & Analysis

Amryt Pharma logo

About Amryt Pharma Stock (NASDAQ:AMYT)

Key Stats

Today's Range
$14.63
$14.76
50-Day Range
$14.55
$14.70
52-Week Range
$6.41
$14.77
Volume
2.39 million shs
Average Volume
757,360 shs
Market Capitalization
$940.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Receive AMYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter.

AMYT Stock News Headlines

Alembic Pharmaceuticals Ltd.
AMYT Historical Data
Top secret Trump trades?
As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”
Amryt Pharma Stock (NASDAQ:AMYT), Dividends
See More Headlines

AMYT Stock Analysis - Frequently Asked Questions

Amryt Pharma plc (NASDAQ:AMYT) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.66. The business earned $49.33 million during the quarter. Amryt Pharma had a positive trailing twelve-month return on equity of 1.70% and a negative net margin of 8.19%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amryt Pharma investors own include Alibaba Group (BABA), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Teladoc Health (TDOC), NIO (NIO), Block (SQ) and Tesla (TSLA).

Company Calendar

Last Earnings
11/05/2020
Today
11/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AMYT
Fax
N/A
Employees
2,020
Year Founded
N/A

Profitability

Net Income
$1 million
Pretax Margin
-0.56%

Debt

Sales & Book Value

Annual Sales
$222.54 million
Cash Flow
$0.98 per share
Book Value
$5.58 per share

Miscellaneous

Free Float
60,343,000
Market Cap
$940.21 million
Optionable
Not Optionable
Beta
0.84
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:AMYT) was last updated on 11/27/2024 by MarketBeat.com Staff
From Our Partners